H. Q. Han

Reversal of Cancer Cachexia and Muscle Wasting by ActRIIB Antagonism Leads to Prolonged Survival

D. Lacey, A. Goldberg, T. Boone, 2010, Cell.

Targeting the myostatin signaling pathway to treat muscle wasting diseases

W. Mitch, H. Q. Han, 2011, Current opinion in supportive and palliative care.

Complete reversal of muscle wasting in experimental cancer cachexia: Additive effects of activin type II receptor inhibition and β‐2 agonist

F. López‐Soriano, S. Busquets, J. M. Argiles, 2016, International journal of cancer.

Pharmacological inhibition of myostatin suppresses systemic inflammation and muscle atrophy in mice with chronic kidney disease

W. Mitch, E. Lin, Zhaoyong Hu, 2011, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

Myostatin/activin pathway antagonism: molecular basis and therapeutic potential.

A. Goldberg, W. Mitch, Xíaolan Zhou, 2013, The international journal of biochemistry & cell biology.

Myostatin blockage using actRIIB antagonism in mice bearing the Lewis lung carcinoma results in the improvement of muscle wasting and physical performance

F. López‐Soriano, S. Busquets, J. M. Argiles, 2011, Journal of cachexia, sarcopenia and muscle.

Inhibiting myostatin signaling partially mitigates structural and functional adaptations to hindlimb suspension in mice

Andrea M. Hanson, A. M. Hanson, B. Harrison, 2023, npj Microgravity.

Intestinal neuronal dysplasia presenting as psoas abscess: A case report

H. Q. Han, Shu Chen, Bingbing Ren, 2022, Frontiers in Surgery.

Cachexia-II during Cancer α Cytokine-Inducible Ubiquitin Ligase E 3 Regulation of Protein Catabolism by Muscle-Specific and Updated

D. Lacey, V. Baracos, W. J. Boyle, 2004 .

Myostatin/activin pathway antagonism: molecular basis and therapeutic potential.

A. Goldberg, W. Mitch, H. Q. Han, 2013, The international journal of biochemistry & cell biology.